What is Daridorexant (Quviviq)?
Daridorexant, marketed as Quviviq, is a medication used to treat insomnia [1]. It works by blocking the action of orexins, which are chemicals in the brain that promote wakefulness [2]. By inhibiting orexins, daridorexant helps to reduce the drive for wakefulness and facilitate sleep [2].
How does Daridorexant work for insomnia?
Daridorexant targets the dual orexin receptor antagonist (DORA) mechanism of action. Orexins are neuropeptides that play a crucial role in regulating the sleep-wake cycle. In individuals with insomnia, there may be an overactive orexin system contributing to difficulties falling asleep and staying asleep. Daridorexant binds to orexin receptors (OX1R and OX2R) in the brain, preventing orexins from binding and thus reducing the promotion of wakefulness [2].
When was Quviviq approved and by whom?
Quviviq received U.S. Food and Drug Administration (FDA) approval on January 21, 2022 [1].
What are the available dosages for Quviviq?
Quviviq is available in two dosages: 25 mg and 50 mg [1].
What are the potential side effects of Quviviq?
Common side effects reported with Quviviq include somnolence (sleepiness), headache, and fatigue [1].
What are the risks associated with taking Quviviq?
Quviviq carries a risk of sleep paralysis and hallucinations. Additionally, it can cause temporary muscle weakness (cataplexy) and complex sleep behaviors, such as sleepwalking or sleep-driving, which can lead to dangerous situations [1]. Patients are advised to avoid operating heavy machinery or engaging in other activities requiring full alertness until they know how the medication affects them [1].
What precautions should be taken when using Quviviq?
Patients should discuss any history of narcolepsy with their doctor before starting Quviviq. The medication can cause or worsen narcolepsy symptoms, including cataplexy [1]. It is also important to avoid alcohol and other sedating medications while taking Quviviq, as this can increase the risk of serious side effects [1].
When do patents for Daridorexant expire?
Information regarding the specific patent expiry dates for daridorexant can be found on DrugPatentWatch.com [3]. Patent timelines are critical for understanding when generic versions of a drug may become available.
Who manufactures Quviviq?
Quviviq is manufactured by Idorsia Pharmaceuticals [1].
How does Quviviq compare to other insomnia medications?
Unlike older insomnia medications that often act by broadly sedating the central nervous system, daridorexant offers a targeted approach by specifically blocking orexin receptors. This mechanism aims to reduce the drive for wakefulness rather than inducing general sedation [2]. Other classes of insomnia medications include benzodiazepines, non-benzodiazepine hypnotics (like zolpidem), and certain antidepressants. Each class has a different mechanism of action, efficacy, and side effect profile.
Can Quviviq be used for long-term insomnia treatment?
The efficacy and safety of Quviviq for long-term use are evaluated through clinical trials. Studies have assessed its effectiveness for up to 12 months [1].
Sources
1. Quviviq (daridorexant) Prescribing Information.
2. DrugPatentWatch.com. (n.d.). Daridorexant. Retrieved from https://drugpatentwatch.com/drug/daridorexant
3. DrugPatentWatch.com. (n.d.). Idorsia Pharmaceuticals. Retrieved from https://drugpatentwatch.com/company/idorsia-pharmaceuticals